

## Supplemental Approvals

### Generic Name (Trade Name—Company)

May 14, 2018

**Polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride, and potassium chloride for oral solution**

*(Plenvu—Valeant/Salix)*

**Lower-volume bowel cleansing prep for colonoscopies receives FDA approval**

### Uses/Notes

[Salix Pharmaceuticals announced](#) FDA approval of polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride, and potassium chloride for oral solution, a lower-volume (1L) polyethylene glycol based (PEG) bowel preparation, under the trade name Plenvu.

Plenvu is the lowest, total-volume preparation bowel cleanser available in the United States, according to Salix.

Approval was based on multiple Phase III clinical trials, including the NOCT study, which compared Plenvu versus a trisulfate bowel cleansing solution (Suprep) using a two-day split-dosing regimen in adults. Both primary endpoints were met, achieving noninferior overall bowel cleansing success and “excellent plus good” cleansing of the ascending colon.

Plenvu is also the only FDA-approved bowel cleanser to offer split dosing on the same day as the colonoscopy procedure.

### Source URL:

<http://aphanet.org/supplemental-approvals/lower-volume-bowel-cleansing-prep-colonoscopies-receives-fda-approval>

A<sub>PhA</sub> DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in A<sub>PhA</sub> DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of A<sub>PhA</sub>. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in A<sub>PhA</sub> DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.